Search

Your search keyword '"Hogan, William J."' showing total 1,345 results

Search Constraints

Start Over You searched for: Author "Hogan, William J." Remove constraint Author: "Hogan, William J." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
1,345 results on '"Hogan, William J."'

Search Results

1. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience

5. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

6. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

8. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

10. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

11. A Day 14 Endpoint for Acute GVHD Clinical Trials

12. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

13. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

14. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

15. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

17. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

18. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

19. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

23. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

24. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

27. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

30. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

31. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

33. Factors Predicting Survival in Patients with TP53-Mutated Myeloid Neoplasms Following Allogeneic Stem Cell Transplant

34. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis

35. Coronary Artery Calcium As a Predictor of Non-Relapse Mortality and Overall Survival in Patients Undergoing Post-Transplant Cyclophosphamide As Gvhd Prophylaxis

36. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms

37. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial

38. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)

40. Impact of Wilms Tumor (WT1) Mutation on Relapse and Overall Survival in Acute Myeloid Leukemia Patients Following Allogenic Stem Cell Transplantation

42. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome

43. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd

44. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms

45. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

46. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

47. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia

48. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation

50. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Catalog

Books, media, physical & digital resources